Business Wire

Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth

Share

Almirall's unique dedication to medical dermatology and innovation - combined with its commercial excellence - fuel an era of sustained double-digit growth (net sales CAGR 2023-2030) and profitability enabling the company to reach more patients with relevant and impactful productsGrowth of Almirall’s psoriasis and atopic dermatitis franchises is anticipated to lead to over 800 million in annual peak sales in biologics, driven by Ebglyss® and Ilumetri®Strategic investments in commercial excellence, R&D and science leadership provide the basis for realising Almirall’s market potential as European leader in medical dermatology

Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, commercial excellence, and its continued investment in R&D to innovate and advance science.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113044812/en/

null

Almirall HQ in Barcelona (Photo: Business Wire)

Almirall combines the strengthening of its growth drivers, particularly the biologics products, with the continued growth of its broad portfolio of medical dermatology solutions, including Klisyri®, Wynzora®, and Seysara®. Almirall’s commercial excellence has been demonstrated by the successful launches of biologics across key markets in Europe. The success of the key growth drivers of Almirall has enabled the company to adjust the anticipated peak sales figures for the biologics portfolio to more than 800MM Eur annually comprising of expected peak sales for Ebglyss® of above 450MM Eur, and Ilumetri® of above 300MM Eur.

This development sees Almirall at a turning point entering an era of sustained double-digit growth (net sales CAGR 2023-2030) that is enabled by the previous investments into commercial capabilities for the launch of breakthrough assets, into capabilities, expertise, and infrastructure. This growth will mainly be driven by biologics which are well placed to take significant market share in these segments that show sustained overall increase and a transition of more patients to advanced treatment options.

Importantly, Almirall will continue to invest in its leading R&D capabilities in medical dermatology driving science leadership and enabling the company to develop disruptive and innovative products that build sustainable future growth as a leader in medical dermatology.

Medical Dermatology: Significant unmet needs and growth potential

Medical dermatology continues to be a pharmaceutical sector with significant unmet needs based on the severe patient impact of a wide range of dermatological diseases, the many uncontrolled patients with chronic diseases, increasing numbers of diagnoses, and the transition of more patients to advanced treatments. Almirall has significant potential for growth in this sector due to its dedication to medical dermatology, commercial capabilities, close collaboration with the medical community, and its proven end-to-end capabilities across the entire value chain. This enables Almirall to give patients and the medical community access to innovative and relevant solutions and contribute to improving their lives.

The company has continuously invested around 12% of its Net Sales in R&D over many years, laying the foundation for continued growth and acceleration in the future and creating and advancing a strong pipeline in key areas, both in clinical and preclinical stages.

Almirall has a broad range of collaborations that help to advance science and enable the development of disruptive new treatments across different modalities. The company continues to focus on building collaborations with partners that have new platforms and technologies to further develop its innovative pipeline. We access the latest available technologies, including small molecules, biologics, and other modalities such as mRNA, for example through the multi-target alliance with etherna to discover and develop innovative and disruptive mRNA / LNP therapies.

"2025 is a turning point for Almirall as we are entering an era of sustained double-digit growth of our net sales CAGR to 2030, and increased EBITDA margins to around 25% by 2028. We are dedicated to improving patients' lives and advancing medical dermatology through our leading research and development initiatives and giving patients access to novel and impactful treatment options – now and in the future," stated Carlos Gallardo, CEO and President of Almirall. "We continue with our sustained investment in R&D to lead science, innovation and excellence in medical dermatology. Almirall is a partner of choice for dermatologists and together we will impact more patients' lives in line with our company’s growth.

Our robust financial situation enables us to invest in long-term growth opportunities which are aligned with our business strategy and ambition as leaders in medical dermatology. By building on our strong portfolio, and making strategic investments, we are well-positioned to meet our ambitious objectives and generate long-term value for shareholders. Our primary advantage lies in our collaborative mindset, agility, and ability to seize opportunities swiftly. This approach also allows us to distribute development costs efficiently,” stated Mike McClelllan, Almirall's CFO.

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit almirall.com

Disclaimer

This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113044812/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Capcom’s Resident Evil Requiem, the Latest Title in the Series, Also Coming to Nintendo Switch 2 on February 27, 2026!16.9.2025 15:00:00 CEST | Press release

– Additionally, two other Resident Evil series titles to be released for the console on the same date in step with Capcom’s multi-platform strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series scheduled for release on February 27, 2026, for PlayStation®5 system, Xbox Series X|S, and PC, will also be released for Nintendo Switch™ 2 at launch. In addition, Resident Evil 7 biohazard and Resident Evil Village, two other titles in the series, will also be released for Nintendo Switch 2 on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916064724/en/ Resident Evil Requiem Key Art Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development experience cultivated over numerou

Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production16.9.2025 15:00:00 CEST | Press release

Human insight and autonomous agents work together to transform operations, enhance efficiency, improve safety, and unlock new value across the enterprise. Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/ Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectiv

GlobalPlatform to Drive Next Phase of Growth for PSA Certified, Accelerating Security Adoption16.9.2025 15:00:00 CEST | Press release

Founded by Arm and industry partners, PSA Certified will continue to evolve under GlobalPlatform’s governance as the trusted global standard for secure connected devices GlobalPlatform announced today it will assume governance of PSA Certified, the global security certification scheme launched by Arm and key partners in 2019. In this next phase of growth, GlobalPlatform—the global standards organization for secure digital services and devices—will drive further collaboration, broader industry participation, and greater regulatory alignment for PSA Certified. Since its launch, PSA Certified has become a globally adopted framework that helps manufacturers and developers build secure connected products based on a Root of Trust. It aligns key security components—such as device identity, cryptography, attestation, and secure boot—with certification needs, regulatory requirements, and global best practices. To date, more than 250 products — spanning silicon, software, and devices—have been c

Moody’s Agentic Solutions to Automate Complex Workflows and Speed Human Decision-Making16.9.2025 14:00:00 CEST | Press release

Moody’s today announced Agentic Solutions, a groundbreaking addition to its suite of AI-powered offerings designed to transform how organizations make decisions in complex, high-stakes environments. The new solutions empower organizations to act with greater speed, precision, and confidence than ever before, reshaping how risk is decoded, opportunities are identified, and decisions are made. “For over a century, our customers have looked to Moody’s for premium data, trusted insights, and cutting-edge solutions to help them make better, more informed decisions,” said Rob Fauber, President and CEO of Moody’s. “Agentic Solutions is a natural extension of our legacy of investment and innovation – anchored in the strength of our industry leading data-estate and the depth of our people’s analytical skills. By integrating agentic capabilities into the workflows of our customers, we are supercharging the speed and precision at which we can help our customers understand risk and unlock opportun

Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran16.9.2025 14:00:00 CEST | Press release

VELA to operate the world’s first sailing cargo trimaran powered by 100 percent wind when at sea1 to sail between Europe and the U.S.Takeda to become the first biopharmaceutical company to ship its products on VELA’s wind-powered trimaran, starting a new era of sustainable shipping in pharma Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the U.S. using VELA’s first-of-its-kind sailing cargo trimaran. VELA designed and will operate a fleet of new generation sailing cargo vessels, powered 100 percent by wind when at sea. Purpose-built to handle pharmaceutical products, VELA will offer reliable, secure and ultra-low-emission sea freight shipping. The maiden voyage is planned for late 2026. VELA’s new wind-powered sea freight will offer a climate-conscious alternative to other transportation for the pharmaceutical industry – cutting use-relat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye